Diabetes giant Novo Nordisk has opened a new front in its rare disease R&D, thanks to an acquisition agreement with Prothena focusing on drugs for ATTR amyloidosis. The Danish drugmaker is paying ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback